Send the following on WhatsApp
Continue to Chathttps://nl.marketscreener.com/koers/aandeel/SYNACT-PHARMA-AB-120973321/nieuws/Synact-Pharma-kondigt-topline-gegevens-aan-van-de-12-weken-durende-Expand-P2b-klinische-studie-bij-e-44766250/?utm_source=whatsapp&utm_medium=social&utm_campaign=share